Professor Benhar’s Research group currently focuses on four major topics:
1) Isolation and characterization of recombinant human antibodies for immunotherapy of various diseases.
2) Evaluation of novel formats of bispecific antibodies and of antibody-toxin fusion proteins as potential anti-cancer agents.
3) Evaluation of death switches that are activated by viral proteases (published in the field of Hepatitis C virus) for potential eradication of virus-infected cells.
4) Application of filamentous phages as targeted drug-carrying nanomedicines for eradication of pathogenic bacteria and fungi.
1) Isolation and characterization of recombinant human antibodies for immunotherapy of various diseases.
2) Evaluation of novel formats of bispecific antibodies and of antibody-toxin fusion proteins as potential anti-cancer agents.
3) Evaluation of death switches that are activated by viral proteases (published in the field of Hepatitis C virus) for potential eradication of virus-infected cells.
4) Application of filamentous phages as targeted drug-carrying nanomedicines for eradication of pathogenic bacteria and fungi.
Prof. Benhar serves as a consultant to several Israeli Biotech companies, including:
- AIT (developing antibodies for clinical applications)
- CEACAM (developing anti-cancer antibodies)
- GreenVision (developing advances imaging systems)
- SeraSense Biotech (developing anti-cancer antibodies)
- MedGenics (developing drug-producing skin grafts).
Contact info:
Prof. Itai Benhar, PhD (full bioagrphy)
Cell research and Immunology Department,
The Shmunis School of Biomedicine and Cancer Research
The George S. Wise Faculty of Life Sciences
